Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

EyePoint Pharmaceuticals, Inc. - Common Stock (NQ:EYPT)

5.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
Earnings Scheduled For March 5, 2025
Via Benzinga
Analyst Ratings For EyePoint Pharmaceuticals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Government
Exposures Political
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
EYPT stock results show that EyePoint Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
EYPT stock results show that EyePoint Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.